Skip to content
ApprovedFDA approved

HMG (Menopur / Pergonal)

Prescription fertility hormone mixture that athletes who have used steroids try in order to restart their own hormone production; banned in sport.

Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

HMG (Menopur / Pergonal) vial

DETAILED OVERVIEW

What is HMG (Menopur / Pergonal)?

HMG (human menopausal gonadotropin) is a hormone mixture purified from the urine of postmenopausal women, containing FSH and LH in roughly equal proportions. In men, the former supports sperm production and the latter stimulates testosterone production. As a prescription medicine (Menopur) it is used in fertility treatment; its predecessor, Pergonal, was withdrawn worldwide around 2005 because of a theoretical risk of infection.

After long, strong hormonal suppression, steroid users try it to restart their own production, because unlike HCG, which only mimics LH, it replaces both hormones. Estrogen levels may rise (breast growth, water retention, mood swings), and acne, headache, reactions at the injection site, allergy and, rarely, a blood clot can occur. It cannot be used with hormone-dependent tumors, and it does not work if the testicle is faulty to begin with (for example in Klinefelter syndrome). It is banned year-round in competitive sport. In men, only a few smaller studies have been done, mostly in patients with hormone deficiency.

Mechanism

Mixture of follicle-stimulating and luteinizing hormone from urine

Half-life

FSH ~24-36 h / LH ~20 h (mixed component decay)

Onset

Test rise 5-10 days, spermatogenesis restart 4-8 weeks

Legal status

EMA Rx Menopur (Ferring 2002), USA FDA Rx Menopur (2005), WADA S2 (banned)

Data console

Lab data

Androgenic:AnabolicN/A (not an AAS; FSH + LH indirect stimulus)
AR bindingFSH-FSHR Kd ~0.1 nM (Sertoli), LH-LHCGR Kd ~0.1 nM…
Active half-lifeClinical effect 3-5 days (mixed component)
Detection windowWADA-accredited immunoassay urinary FSH + LH detection – 7-14 days after chronic protocol, 3-5 days after single bolus.
AromatizationIndirect: testicular FSH+LH stimulus → endogenous Test → secondary peripheral E2 (similar magnitude to HCG, slightly lower because Sertoli activity dominates vs Leydig). In AAS-PCT context, E2 rebound monitoring is needed at higher HMG doses (>150 IU EOD).
HepatotoxicityNo hepatic stress – protein-based SC or IM injection.

Safety

Side effects, stop signs, contraindications

Side effects · 7

  • Estrogen rebound: FSH+LH stimulation raises endogenous testosterone and secondarily E2, at higher doses (>150 IU EOD) causing gynecomastia, water retention and mood swings.
  • Injection-site reactions (SC/IM): pain, redness, swelling, itching, rarely haematoma or sterile abscess at the injection site.
  • Hypersensitivity and allergic reactions to the urine-derived protein: urticaria, rash, rarely severe systemic (anaphylactic) reactions.
  • Headache, fatigue, abdominal discomfort and bloating, nausea – common, dose-dependent, usually mild gonadotropin side effects.
  • Testicular tenderness and transient enlargement from the dual Leydig+Sertoli stimulus; risk of receptor downregulation with prolonged (>6 weeks) monotherapy.
  • Acne and oily skin, mood irritability secondary to rising endogenous androgen levels.
  • Thromboembolic risk (rare): the classic gonadotropin class warning notes possible venous/arterial thrombosis, especially with congenital or acquired thrombophilia.

Contraindications · 7

  • Known hypersensitivity to HMG, menotropins or any excipient (urine-derived protein sensitization).
  • Hormone-dependent tumors or their suspicion: testicular, prostate, pituitary or hypothalamic tumor – gonadotropin stimulation may promote their progression.
  • Infertility of a cause on which HMG is ineffective (Klinefelter syndrome, Y-chromosome deletion, primary testicular failure) – no therapeutic benefit.
  • Untreated or poorly controlled endocrine disorder (thyroid, adrenal dysfunction, hyperprolactinemia) – must be corrected first.
  • Pre-pubertal males and childhood – not indicated in this user context.
  • Active thromboembolic disease or severe thrombophilia – relative contraindication due to the gonadotropin class thrombosis risk, requires close monitoring.
  • Concurrent exogenous TRT (chronic testosterone) – Leydig cells are suppressed, HMG stimulation is ineffective and pointless in this context.

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about HMG (Menopur / Pergonal)?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.